Abstract
Glypican-3 (GPC3) is a promising tumor marker for hepatocellular carcinoma (HCC) diagnosis with high sensitivity and specificity. The aim of this study was to establish an immunohistochemical detection method for GPC3 using the 7D11 monoclonal antibody (7D11 mAb) and evaluate its application for HCC diagnosis. The feasibility of the 7D11 mAb was evaluated by immunohistochemistry performed on adjacent normal liver and intrahepatic cholangiocarcinoma (ICC) samples, Furthermore, the serum GPC3 levels were evaluated in 40 HCC patients, 7 ICC patients and 50 healthy donors. The results showed that GPC3 was expressed in 85% of HCC tissues (34/40), but was undetectable in ICC tissues and adjacent normal tissues.GPC3 was significantly increased in the serum of HCC patients (17/40, 42.5%) but was undetectable in the serum of ICC patients (0/7, 0%) and healthy donors(0/50, 0%). This prospective study evaluated the clinical usefulness of 7D11 mAb for GPC3 detection in HCC patients. In conclusion, the use of 7D11 mAb might be good for GPC3 large-scale applications for clinical diagnosis of HCC.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Parkin D M, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer, 2001, 94: 153–156
Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol, 2006, 12: 1175–1181
Taketa K. α-fetoprotein: revaluation in hepatology. Hepatology, 1990, 12: 1420–1432
Filmus J, Selleck S B. Glypicans: proteoglycans with a surprise. J Clin Invest, 2001, 108: 497–501
Zhu Z W, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 2001, 48: 558–564
Zhou X P, Wang H Y, Yang G S, et al. Cloning and expression of MXR7 gene in human HCC tissue. World J Gastroenterol, 2000, 6: 57–60
Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res, 2004, 64: 2418–2423
Zhang Q Y, Qin X, Zhen L, et al. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem, 2010, 43: 1003–1008
El-Shenawy S Z, Sabawi M M E1, Sheble N, et al. Diagnostic role of serum glypican-3 as a tumor marker for hepatocellular carcinoma. Nat Sci, 2012, 10: 32–38
Wang F H, Yip Y C, Zhang M, et al. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. J Clin Pathol, 2010, 63: 599–603
Mariana C, Ian R W, Morris S, et al. Glypican-3 a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology, 2003, 125: 89–97
Llovet J M, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology, 2006, 131: 1758–1767
Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis, 2010, 30: 017–025
Bruix J, Morris S. Management of hepatocellular carcinoma: an update. Hepatology, 2011, 53: 1020–1022
Zhu Z W, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 2001, 48: 558–564
Yutaka M, Shumpei I, Hiroko I, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer, 2003, 103: 455–465
Wang X Y, Degos F, Dubois S, et al. Glypican-3 expression in Hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol, 2006, 37: 1435–1441
Liu H, Li P, Zhai Y, et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol, 2010, 16: 4410–4415
Soha ZE1 S, Maha ME1 S, Nashwa S, et al. Diagnostic role of serum glypican-3 as a tumor marker for hepatocellular carcinoma. Nat Sci, 2012, 10: 32–38
Author information
Authors and Affiliations
Corresponding authors
Additional information
This article is published with open access at Springerlink.com
Contributed equally to this work
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Yu, J., Ma, Q., Zhang, B. et al. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis. Sci. China Life Sci. 56, 234–239 (2013). https://doi.org/10.1007/s11427-013-4451-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-013-4451-y